-The Times of India NEW DELHI: Branded medicines cost 2-15 times more than non-branded generic medicines sold at Jan Aushadhi stores. For example, a 10-tablet strip of Diclofenac SR (100mg), a popular pain killer, costs Rs 51.91 whereas the same generic medicine costs only Rs 3.35 at Jan Aushadhi stores. An 100 ml bottle of cough syrup manufactured and marketed by drug companies costs Rs 33 while those sold at Jan Aushadhi...
More »SEARCH RESULT
Total Matching Records found : 242
Drug price policy under SC glare
-The Telegraph New Delhi: The Supreme Court today ticked off the government for "dilly dallying" on an affordable drug pricing policy, following a petition that said the delay was aimed at pushing through suggestions of the powerful manufacturers' lobby. A bench of Justices G.S. Singhvi and Gopala Gowda asked the Centre to respond within six weeks. The All India Drug Action Network (AIDAN) had filed the application saying the government was delaying a...
More »Price control, IP Act & regulatory framework: Revisiting some imp issues about Indian pharma-Ramesh Adige
-The Economic Times Over a year ago, I had written a piece, Quo Vadis, Indian Pharma? (ET, May 11, 2012), in this column. Some key issues were highlighted in the article. Perhaps it is time to revisit the subject and bring out some current issues. Price control: Hurray, the department of pharmaceuticals has come out with a new non-intrusive price control methodology, moving from the cost-based model to the average market price...
More »Kerala tackles prejudice and prices -C Maya
-The Hindu The State population stands at a little over three crore, but average consumption of drugs is three times the national average In Kerala, where people have a marked preference for branded drugs, where the most expensive brand is considered the best, and only those brands pushed by doctors sell, the new Drug (Prices Control) Order, which is expected to cut prices by 20-25 per cent, may not have much of...
More »Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan
-The Times of India NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been "of unacceptable quality". Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable...
More »
